Keywords
isolated coronary heart disease
batokines
FGF21
VEGFA
How to Cite
Abstract
The article analyzes the dynamics of batokine levels: vascular endothelial growth factor A (VEGFa) and fibroblast growth factor (FGF-21) in patients with comorbidity of coronary heart disease (CHD) and obesity against the background of therapy. The aim of the research was to study the dynamics of FGF-21 and VEGFa levels in individuals with comorbidity of CHD and obesity against the background of therapy. 130 people aged from 25 to 85 were examined: Group I included 70 patients with CHD in combination with obesity, Group II – 35 patients with isolated CHD, Тhe control group (Group III) included 25 healthy people without any cardiovascular diseases. The Group I included 26 (37.1%) patients with the Ist degree of obesity, 24 (34.3%) patients with the IInd degree of obesity, and 20 (28.6%) with the IIIrd degree of obesity. During the study, standard ethical requirements for similar studies were met, which was confirmed by the conclusion of the Bioethics Committee of the Kharkiv National Medical University. In the research FGF21 and VEGFA levels were established. These indicators were restored after treatment. The dynamics of the decrease in the levels of FGF21 (by 23.6 pg/ml) and VEGFA (by 11.1 pg/ml) after treatment was better in patients of the I group (p<0.001). In the II group, there was a decrease in the levels of FGF21 (by 10.5 pg/ml; p=0.001) and VEGFA (by 2.2 pg/ml; p=0.154). According to obesity levels, the dynamics of FGF21 recovery was better for grades I (by 29.1 pg/ml; p=0.004) and II (by 55.7 pg/ml; p<0.001). A significant (p<0.001) increase in the level of FGF21 after treatment by 22.5 pg/ml was observed in degree III obesity. Probable (p<0.001) better dynamics of recovery of VEGFA level was observed in obesity of III degree (decrease by 13.8 pg/ml), compared to II and I degrees (decrease by 9.8 pg/ml and 10.2 pg/ml). Treatment of patients with CHD on the background of obesity determined its effectiveness in restoring the levels of FGF21 and VEGFA.
Keywords: coronary heart disease and obesity comorbidity, isolated coronary heart disease, batokines, FGF21, VEGFA.
References
Remus Popa A, Fratila O, Rus M, Anca Corb Aron R, Mihai Vesa C, Pantis C et al. Risk factors for adiposity in the urban population and influence on the prevalence of overweight and obesity. Exp Ther Med. 2020;20(1):129-33. DOI: 10.3892/etm.2020.8662. PMID: 32509005.
GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659-724. DOI: 10.1016/S0140-6736(16)31679-8. PMID: 27733284.
Rai SS, Syurina EV, Peters RMH, Putri AI, Zweekhorst MBM. Non-Communicable Diseases-Related Stigma: A Mixed-Methods Systematic Review. Int J Environ Res Public Health. 2020;17(18):6657. DOI: 10.3390/ijerph17186657. PMID: 32932667.
Shaposhnikov DI, Radomskyi OV. Analysis of the epidemiological situation regarding diseases of the circulatory system in Ukraine and Pakistan : abstracts of reports of the 75th All-Ukrainian student scientific conference "Medical students' conference in Poltava" (MEDSCOP 2019). Poltava, Ukraine; 2019. P. 107. [In Ukrainian].
Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health. 2021;21(1):401. DOI: 10.1186/s12889-021-10429-0. PMID: 33632204.
Sarrafzadegan N, Mohammmadifard N. Cardiovascular Disease in Iran in the Last 40 Years: Prevalence, Mortality, Morbidity, Challenges and Strategies for Cardiovascular Prevention. Arch Iran Med. 2019;22(4):204-10. PMID: 31126179.
Jagannathan R, Patel SA, Ali MK, Narayan KMV. Global Updates on Cardiovascular Disease Mortality Trends and Attribution of Traditional Risk Factors. Curr Diab Rep. 2019;19(7):44. DOI: 10.1007/s11892-019-1161-2. PMID: 31222515.
Cortesi PA, Fornari C, Madotto F, Conti S, Naghavi M, Bikbov B, et al. GBD 2017 Italy Cardiovascular Diseases Collaborators. Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017. Eur J Prev Cardiol. 2021;28(4):385-96. DOI: 10.1177/2047487320949414. PMID: 33966080.
Tilz RR, Lenarczyk R, Scherr D, Haugaa KH, Iliodromitis K, Pürerfellner H et al. Management of ventricular tachycardia in the ablation era: results of the European Heart Rhythm Association Survey. Europace. 2018;20(1):209-13. DOI: 10.1093/europace/eux332. PMID: 29186419.
Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J Am Coll Cardiol. 2019;74(20):2529-32. DOI: 10.1016/j.jacc.2019.10.009. PMID: 31727292.
GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1859-922. DOI: 10.1016/S0140-6736(18)32335-3. PMID: 30415748.
Andonieva NM, Berezin OIe, Berezin OO, Bilovol OM, Bob AO, et al. Arterial hypertension and comorbidity: monograph. Kharkiv: KhNMU; 2019. 176 s. [In Ukrainian].
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. DOI: 10.1016/j.jacc.2020.11.010. PMID: 33309175.
Gonzalez-Rivas JP, Mechanick JI, Infante-Garcia MM, Medina-Inojosa JR, Pavlovska I, Hlinomaz O, et al. The Prevalence of Dysglycemia-Based Chronic Disease in a European Population – a New Paradigm to Address Diabetes Burden: A Kardiovize Study. Endocr Pract. 2021;27(5):455-62. DOI: 10.1016/j.eprac.2020.10.003. PMID: 33685667.
Janssen JAMJL. Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer. Int J Mol Sci. 2021;22(15):7797. DOI: 10.3390/ijms22157797. PMID: 34360563.
Jung E, Romero R, Yeo L, Gomez-Lopez N, Chaemsaithong P, Jaovisidha A, et al. Am J Obstet Gynecol. 2022;226(2S):S844-S866. DOI: 10.1016/j.ajog.2021.11.1356. PMID: 35177222.
Wittenbecher C, Cuadrat R, Johnston L, Eichelmann F, Jäger S, Kuxhaus O, et al. Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology. Nat Commun. 2022;13(1):936. DOI: 10.1038/s41467-022-28496-1. PMID: 35177612.
Manrique-Acevedo C, Chinnakotla B, Padilla J, Martinez-Lemus LA, Gozal D. Obesity and cardiovascular disease in women. Int J Obes (Lond). 2020;44(6):1210-26. DOI: 10.1038/s41366-020-0548-0. PMID: 32066824.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. DOI: 10.1093/eurheartj/ehz425. PMID: 31504439.
Hebebrand J, Holm JC, Woodward E, Baker JL, Blaak E, Durrer-Schutz D, et al. A proposal of the European Association for the Study of Obesity to Improve the ICD-11 Diagnostic Criteria for Obesity Based on the Three Dimensions Etiology, Degree of Adiposity and Health Risk. Obes Facts. 2017;10(4):284-307. DOI: 10.1159/000479208. PMID: 28738325.
Zheng X, Zhu Z, Guo D, Zhong C, Xu T, Peng Y, et al. Prognostic value of plasma fibroblast growth factor 21 among patients with acute ischemic stroke. Eur J Neurol. 2021;28(3):844-51. DOI: 10.1111/ene.14683. PMID: 33320402.
Lee CH, Woo YC, Chow WS, Cheung CYY, Fong CHY, Yuen MMA et al. Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus. J Am Heart Assoc. 2017;6(6):e005344. DOI: 10.1161/JAHA.116.005344. PMID: 28588089.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.